We are proud to share that we’ve secured Medicare reimbursement for the Prosigna® Breast Risk of Recurrence (ROR) test! Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test for eligible patients with early-stage breast cancer, creating a reimbursement path for those patients and their physicians to receive critical genomic information to help guide their treatment. The Prosigna Breast ROR test received coverage and reimbursement for its Technical Assessment submission through Palmetto GBA’s MolDX program. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) breast cancer who meet the applicable Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes.* | Resources | 🔗 Read the full announcement - investor.veracyte.com/news-r… 📄 Prosigna Breast ROR test - veracyte.com/tests/prosigna-… #Medicare #BreastCancer #PrecisionOncology #ProsignaBreastTest #TeamVeracyte | Notes | * Centers for Medicare & Medicaid Services. MolDX Breast Cancer Assay Prosigna. Local Coverage Determination L36125. cms.gov/medicare-coverage-da… ** This article contains forward-looking statements, which involve risks and uncertainties. For more information, please visit veracyte.com/legal/cautionar… *** Prosigna testing is available in the United States as a laboratory developed test (LDT) service and has not been cleared or approved by the FDA. The test is not yet available in New York.

We’re proud to celebrate an important milestone: serving one million patients with our molecular tests. We’ve reached this point by fulfilling our core promise: to empower clinicians with the high-value genomic insights they need to make more confident treatment decisions for their patients. For us, every test is a promise kept. Learn more about our mission to transform #CancerCare for patients all over the world - veracyte.com/company/about-v… #PrecisionOncology #MolecularTesting #CancerDiagnostics #TeamVeracyte

Six studies involving our genomic tests across urologic and breast cancers will be presented at the European Society for Medical Oncology Congress 2026 (#ESMO26) in Madrid, Spain, from October 23rd to October 27th. Together, the studies presented at ESMO will reflect how understanding a tumor’s biology can inform decisions across cancer care, addressing key questions for clinicians and patients alike. | Key Oral Presentation Highlights | 🔹 The first evidence that the Decipher® Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy for patients with clinically very high-risk, nonmetastatic #ProstateCancer 🔹  A late-breaking health economic analysis of Prosigna®-guided chemotherapy decisions for high-risk early #BreastCancer from the Phase III landmark OPTIMA trial | Resources | 🔗 Read the full press release - investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/event/e… 🔗 Explore our portfolio of market-leading tests - veracyte.com/innovation/tech… #PrecisionOncology #MedicalOncology #BladderCancer #DecipherUrologicCancers #ProsignaBreastTest #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

The Veracyte team is in Los Angeles for the American Academy of Otolaryngology–Head and Neck Surgery Annual Meeting and OTO Expo (#OTOMTG26), joining #ENT leaders from October 17th through the 20th to discuss molecular testing for #ThyroidCancer. Stop by #Booth 1001 to talk with our team and learn how the Afirma® Genomic Sequencing Classifier (GSC) uses transcriptome-wide analysis of over 21,000 genes from patient fine-needle aspiration (FNA) samples to help conclusively rule out surgery and confidently guide treatment for #ThyroidNodules. You can also ask our medical team about the latest updates to Afirma® GRID (Genomic Resource for Intelligent Discovery), a proprietary research-use-only* data resource, designed to help advance the understanding of thyroid nodules and thyroid cancer at the molecular level. We look forward to seeing you there! | Resources | 📅 Event information: veracyte.com/company/event/a… 🔗 Explore Afirma GSC: veracyte.com/tests/afirma-th… 🧬 Learn more about Afirma GRID: veracyte.com/innovation/afir… #Otolaryngology #HeadAndNeckSurgery #AfirmaThyroid #TeamVeracyte | Notes | *Afirma GRID data is for research use only and is not intended to guide patient management. ** This article contains forward-looking statements, which involve risks and uncertainties. For more information, please visit veracyte.com/legal/cautionar…

At 47, Bora was balancing an office-based role as a local elected politician when she received a breast cancer diagnosis that came as a complete shock. She had experienced lumpy breasts for 10 to 15 years, with changes that often became more noticeable during her menstrual cycle. When one lump did not go away, she arranged to have it checked. An ultrasound and biopsy confirmed breast cancer. “I cried,” she says. “It was a total shock.” Bora approached the diagnosis in a practical way, drawing on her previous experience as a journalist to research the disease and understand the available information. But the process was still difficult. Referrals, appointments and decisions about surgery meant that roughly two weeks could pass between each step. She was referred to two surgeons while considering how to move forward with treatment as quickly as possible. She chose to be open about her diagnosis and found that talking with friends and loved ones was an important source of support. Living alone, she particularly valued having people around her who could help her process what was happening. After her second surgery, her care team needed to determine whether she required additional chemotherapy. The team told her about the OPTIMA trial, which, according to her team, was investigating whether genomic testing could help guide treatment decisions. Bora had a positive view of clinical research and had already taken part in other studies. She discussed the trial information with friends who were oncologists and decided to participate. Her main concern was whether she might get her hopes up, as she expected that chemotherapy would probably be recommended. “To be honest, I kind of forgot I was involved in it,” she says. Participation involved completing a questionnaire about every three months, focused on lifestyle and how she was feeling. For Bora, the experience reinforced the value of clear, personalized information. “Data and information can be empowering when they are explained properly,” she says. “There are different types of breast cancer, treatment options and decisions. When testing is available alongside appropriate medical advice, it can help patients feel more empowered.” 🩷 In honor of #BreastCancerAwarenessMonth, join us in thanking the people, like Bora, who took part in the OPTIMA trial - veracyte.com/because-they-sa… #BreastCancer #CancerClinicalTrials #BreastCancerResearch #BecauseTheySaidYes #ResearchIsTheReason #BreastCancerJourney

Meet the inaugural winner of the Conquer Cancer®-Veracyte Endowed Young Investigator Award in Breast Cancer Genomics: Dr. Alexandra (Bili) Newman! Dr. Newman is currently finishing her second year of a three-year fellowship in Hematology-Oncology at MD Anderson Cancer Center in Houston, with a clinical and research focus on #BreastCancer. Her YIA project focuses on the role of post-transcriptional PTEN loss as a predictive biomarker of response to PI3K-targeted agents in advanced hormone-receptor positive breast cancer. Recently, Veracyte sat down with Dr. Newman to discuss: 🔹 Her background 🔹 The YIA project and its professional significance 🔹 Why this research is important for patients 🔗 To learn more about Dr. Newman and her work, check out the full interview -  veracyte.com/company/blog/th… #BreastCancerAwarenessMonth #BreastCancerResearch #CancerGenomics #PrecisionOncology #ConquerCancer #TeamVeracyte

Last week, Veracyte team members alongside Christy, a person diagnosed with breast cancer, and her family showed up on the TODAY show plaza in New York City to help kick off #BreastCancerAwarenessMonth! The team arrived, signs in tow, to join the TODAY crowd at Rockefeller Center to help amplify the importance of #BreastCancerResearch and the people who make it possible.  Breast cancer research depends on brave people who say yes to clinical trials. Their courage drives new possibilities leading to better tests and treatments for the people who come next. Christy’s treatment journey reflects the profound impact that clinical trial participants can have on other patients. Christy, a 51-year-old premenopausal mother, was able to avoid chemotherapy after receiving a low Risk of Recurrence score on the Prosigna® Breast Cancer test and consulting with her oncologist. That treatment decision was supported by clinical evidence made possible by participants in the landmark OPTIMA trial. 🩷 HUGE thank you to Christy, her family, and everyone else who showed up to help shine a spotlight on #BreastCancer! 📺 Check out the TODAY Plaza Cam clip here! youtube.com/watch?v=fWmGKkr4… | #BecauseTheySaidYes | 🩷 If you'd like an opportunity to express your gratitude with breast cancer patients in clinical trials, join us in thanking the people who took part in the #OPTIMA trial - becausetheysaidyes.com #CancerClinicalTrials #ResearchIsTheReason

Kathryn lives in the UK with her husband, Rick. The couple have been married for 28 years and have two grown-up daughters. At 50, Kathryn was diagnosed with breast cancer after attending her first routine NHS mammogram. She underwent a mastectomy and had some lymph nodes removed before being referred to a specialist cancer center to discuss her next steps. According to Kathryn, during her meeting with her doctors, she learned about the #OPTIMA trial and the possibility that she might not need chemotherapy. “I was really surprised, as I’d just assumed I’d have to have chemo,” she says. “When I found out that I didn’t, I was over the moon.” Instead of chemotherapy, Kathryn received other recommended treatments, including a targeted cancer drug, which she took for two years. Avoiding chemotherapy meant she was able to continue working as a teacher and maintain a routine close to her life before her diagnosis. “I was able to keep doing the job I loved—teaching—and just got on with a life that was pretty close to how it was pre-diagnosis,” she says. Following this experience, Kathryn says she has discovered a renewed enthusiasm for life. One of her daughters, a personal trainer and strength coach, encouraged her to start going to the gym. She also enjoys spending time in London visiting her other daughter. “It’s given me a new zest for life,” Kathryn says. “Life is good.” Kathryn says she had complete confidence in her clinical team and the trial and never had reservations about taking part. “I know that without patients taking part in research, there won’t be any advances in treatment,” she says. “I was really happy to take part and would encourage other patients to say ‘yes’ too.” 🩷 In honor of #BreastCancerAwarenessMonth, join us in thanking the people, like Kathryn, who took part in the OPTIMA trial - becausetheysaidyes.com #BreastCancer #CancerClinicalTrials #BreastCancerResearch #BecauseTheySaidYes #ResearchIsTheReason #BreastCancerJourney

#TeamVeracyte is here in Las Vegas October 3–6 for #CAP26! Stop by Booth 150 to learn how our tests assess the unique biology of each patient's tumor or nodule to help clinicians answer key questions and make confident decisions for thyroid, prostate, breast, and bladder cancer care. Be sure to ask about: 🔹 Afirma® Genomic Sequencing Classifier:  helps clinicians conclusively rule out surgery and confidently guide treatment for thyroid nodules 🔹 Decipher® Bladder Genomic Classifier: provides deep biological insight into a patient’s bladder cancer to help guide personalized treatment decisions 🔹 Decipher® Prostate Genomic Classifier:  measures the expression of 22 genes in prostate cancer tissue to convey tumor aggressiveness and disease progression risk 🔹 Prosigna® Breast Risk of Recurrence Test: delivers comprehensive genomic insights to help make more informed breast cancer treatment decisions. | Resources | 🔗 Afirma® Genomic Sequencing Classifier - veracyte.com/tests/afirma-th… 🔗 Decipher® Bladder Genomic Classifier - veracyte.com/tests/decipher-… 🔗 Decipher Prostate Genomic Classifier - veracyte.com/tests/decipher-… 🔗 Prosigna® Breast Risk of Recurrence Test - veracyte.com/tests/prosigna-… 🔗 For more event information: veracyte.com/company/event/c… #MolecularTesting #Pathology #PrecisionOncology #MolecularPathology

The Veracyte team is in Las Vegas this week for the College of American Pathologists’ 2026 Annual Meeting (#CAP26), joining leading #Pathology experts from October 3rd through the 6th to highlight the latest advancements in #MolecularTesting. Visit Booth 150 to learn how our portfolio of high-performing molecular tests helps transform uncertainty into clarity across thyroid, prostate, breast, and bladder cancer care. Find out the latest clinical evidence and how our tests assess the unique biology of each patient's tumor or nodule to answer key questions and support confident clinical decision-making. | Tests Featured at CAP | 🔹 Afirma Genomic Sequencing Classifier - veracyte.com/tests/afirma-th… 🔹 Decipher® Bladder Genomic Classifier - veracyte.com/tests/decipher-… 🔹 Decipher Prostate Genomic Classifier - veracyte.com/tests/decipher-… 🔹 Prosigna® Breast Risk of Recurrence Test - veracyte.com/tests/prosigna-… 🔗 For more event information: veracyte.com/company/event/c… #PrecisionOncology #MolecularPathology #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information, veracyte.com/legal/cautionar…

#BreastCancerResearch depends on brave people who say yes to clinical trials. Their courage drives new possibilities, leading to better tests and treatments for the people who come next. 🎀 So, in recognition of #BreastCancerAwarenessMonth, please join us in thanking the people who took part in the OPTIMA trial. | #BecauseTheySaidYes | Based on the OPTIMA trial, more than two-thirds of people with clinically high-risk breast cancer, may safely avoid chemotherapy. The OPTIMA trial showed that the Prosigna test can be used to predict chemotherapy benefit for people with HR+ breast cancer. | The People Who Said Yes | 4,429 people joined OPTIMA across six countries. Because they said “yes” doctors can better support personalized chemotherapy decisions and make sure that the right treatment is given to the right patients. 🩷 Share your thanks here - becausetheysaidyes.com #BreastCancer #CancerClinicalTrials #ResearchIsTheReason

When Aileen was diagnosed with stage three breast cancer, one of her biggest concerns was how treatment would affect her livelihood and her family. Aileen, now 65, lives in the UK with her husband, Kevin. Together, they run a dry-cleaning business where they work six days a week. They are also parents to three daughters. Aileen took part in the OPTIMA clinical trial so that she and her doctor could better understand her breast cancer. Since Aileen’s cancer had spread to a lymph node under her arm, she was eligible for the trial and was randomly assigned to the group receiving a genomic test. Her results showed a low score, indicating that chemotherapy was unlikely to benefit her. Aileen was able to avoid chemotherapy, and instead had a mastectomy followed by hormone therapy. This was an enormous relief for her, as she explained: “If I had to have chemotherapy, I probably would have had to stop working and we might have lost our livelihood, which would have been disastrous.” Avoiding chemotherapy meant Aileen could continue working alongside Kevin throughout her treatment, while maintaining the activities she enjoyed and spending time with her family. “Being able to live the best life possible during cancer treatment is so important for both your physical and mental health,” she says. “I was able to do all the things I love, like going swimming three to four times a week and getting away for the weekend with Kevin.” Looking back, Aileen says she had no reservations about joining the trial. “Science and medicine can’t advance without research, so I was glad to play my part in helping people like me in the future.” 🩷 In honor of #BreastCancerAwarenessMonth, join us in thanking the people, like Aileen, who took part in the OPTIMA trial - becausetheysaidyes.com #BreastCancer #CancerClinicalTrials #BreastCancerResearch #BecauseTheySaidYes #ResearchIsTheReason #BreastCancerJourney

Thyroid Cancer Awareness Month is a chance to broaden our understanding not only of thyroid cancer, but also of the questions and decisions that can arise when a thyroid nodule is discovered. After discovery, providers usually use a thyroid fine-needle aspiration (FNA) biopsy to evaluate the features of nodule cells under a microscope for potential cancer characteristics. If cancer is detected or strongly suspected, the nodule is resected and examined further. If benign, no surgery is usually needed. However, as many as 30% of thyroid FNA biopsies do not clearly show whether a nodule is cancerous or benign. Without a clear answer, patients are left wondering if they have cancer while grappling with a heavy question: Should I proceed with surgery just in case? Historically, many patients with an indeterminate result proceeded to diagnostic surgery, only to learn afterward that their nodules were, in fact, benign. In fact, up to 80% of these surgeries ultimately proved unnecessary because the nodules were not cancerous. In recognition of Thyroid Cancer Awareness Month, we created an article that examines what comes after receiving an indeterminate result, highlighting clinical data that shows how advancements in genomic testing can help resolve uncertainty for many patients. In addition, the piece provides an inside look at how Veracyte supports ongoing research efforts in thyroid cancer and nodule risk stratification. 🔗 Read our thoughts here: veracyte.com/company/blog/in… #ThyroidCancerAwarenessMonth #ThyroidCancer #ThyroidNodules #MolecularTesting #PrecisionMedicine #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties.

We are proud to announce new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial. The results, which will be presented at the #ASTRO26 Annual Meeting (Abstract #312), demonstrate that the Decipher® Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term androgen deprivation therapy (ADT) to dose-escalated radiation, providing Level 1B* prognostic and predictive evidence. | Impact | The findings provide the first evidence that Decipher testing can predict hormone therapy benefit in intermediate-risk prostate cancer, extending its long-established role in assessing the risk of prostate cancer progression to informing treatment selection for patients with intermediate-risk disease. While ADT can reduce the risk of recurrence and distant spread, it can also have metabolic and quality-of-life effects. Because intermediate-risk disease is biologically diverse, clinical variables such as Gleason grade, prostate-specific antigen (PSA) or clinical stage alone may not reveal which patients are most likely to benefit from adding the therapy. The NRG/RTOG 0815 trial analysis helps move #DecipherProstate testing closer to answering  a consequential question in prostate cancer care: Will hormonal therapy make a meaningful difference for this patient? Study author, Angela Jia, M.D., Ph.D. will present the results. | Presentation Details | 📅 Date: Tuesday, September 29 ⏰ Time: 3:55pm – 4:05pm ET 📍 Location: Room 210 *Simon, R. M., Paik, S. & Hayes, D. F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101, 1446–1452 (2009). doi.org/10.1093/jnci/djp335 | Resources| 📄 Read full press release - investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/event/a… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #TeamVeracyte This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: veracyte.com/legal/cautionar…

#TeamVeracyte is in Boston September 26–30 for the American Society for Radiation Oncology Annual Meeting (#ASTRO26)! Stop by Booth 1548 to learn how Veracyte is informing clinical decision-making and advancing research in #RadiationOncology through genomic insights in #ProstateCancer. Ask about: 🔹 Decipher® Prostate Genomic Classifier: a test that supports prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity 🔹 Decipher GRID (Genomic Resource for Intelligent Discovery): a proprietary research-use-only database designed to help advance understanding of urologic cancers at the molecular level | Resources | 🔗 Event details and full presentation schedule - veracyte.com/company/event/a… 📄 Decipher Prostate test - veracyte.com/tests/decipher-… 📄 Decipher GRID data resource - veracyte.com/innovation/deci… #RadOnc #PrecisionOncology #DecipherProstate #DecipherGRID #DecipherUrologicCancers

At #ASTRO2026, a collection of new research will explore how genomic information can help clarify pivotal treatment decisions for patients with cancer. As a key example, join us for an oral presentation from Angela Jia, M.D., Ph.D., that aims to answer a key question: Which individuals with intermediate-risk prostate cancer are most likely to benefit from short-term androgen-deprivation therapy when receiving dose-escalated radiotherapy? In an ancillary analysis of the landmark Phase III NRG/RTOG 0815 clinical trial, Dr. Jia will present findings on whether the Decipher® Prostate Genomic Classifier test can help predict which patients are most likely to benefit from adding short-term androgen deprivation to dose-escalated radiotherapy. | Featured Presentation Information | 📄 Abstract: #312 📅 Date/Time: Tuesday, September 29, 3:55–4:05 p.m. ET 📍 Location: Room 210 We’re also looking forward to additional ASTRO 2026 presentations examining treatment intensification and the role of transcriptomic biomarkers in prostate cancer radiation therapy treatment decisions. | Additional Key Oral Presentations | 🔹 Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis 🎤 Presenter: Shuang Zhao, MD, MSE, University of Texas MD Anderson Cancer Center 📄 Abstract: 6 Date/Time: Sunday, September 27, 1:30–1:40 p.m. ET 📍 Location: Grand Ballroom 🔹The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002 🎤 Presenter: Mark Hurwitz, M.D., FASTRO, New York Medical College/Westchester Medical Center Health 📄 Abstract: 250 Date/Time: Tuesday, September 29, 12:40–12:50 p.m. ET 📍 Location: Room 210 🔹 Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial 🎤 Presenter: Abhishek Solanki, M.D., M.S., Loyola University Medical Center 📄 Abstract: 314 📅 Date/Time: Tuesday, September 29, 4:15–4:25 p.m. ET 📍 Location: Room 210 🔹 Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy 🎤 Presenter: Krishnan Patel, M.D., University of Texas MD Anderson Cancer Center 📄 Abstract: 315 📅 Date/Time: Tuesday, September 29, 5:35–5:40 p.m. ET 📍 Location: Room 205 | Resources | 🔗 For additional presentations and info on Veracyte’s activities at ASTRO 2026: veracyte.com/company/event/a… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #DecipherProstate #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

Eight studies, including analyses from multiple clinical trials, leveraging our Decipher® Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology Annual Meeting (#ASTRO26), taking place from September 26 through September 30 in Boston. | Key Highlights | The presentations include analyses from: 🔹 Phase II and III clinical trials 🔹 Decipher Genomic Research for Intelligent Discovery (#DecipherGRID) research 🔹 National real-world studies Collectively, these presentations will further explore the potential clinical value of understanding tumor biology at the molecular level and how genomic testing can help personalize treatment decisions for #ProstateCancer patients across different stages of disease. Of note, clinical trial analyses will specifically examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation. | Resources | 🔗 Read the full press release - investor.veracyte.com/news-r… 🔗 Event information - veracyte.com/company/event/a… 📄 Decipher Prostate test - veracyte.com/tests/decipher-… 📄 Decipher GRID data resource - veracyte.com/innovation/deci… #RadOnc #PrecisionOncology #ClinicalTrials #RealWorldData #TeamVeracyte Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar…

During Thyroid Cancer Awareness Month, Veracyte recognizes that an indeterminate thyroid nodule result often leads to critical questions about malignancy risk, the potential for unnecessary surgery, and the most appropriate next step. For these patients, every management decision begins with diagnostic clarity. Afirma® Genomic Sequencing Classifier (GSC) delivers a clinically actionable benign or suspicious result, helping clinicians conclusively rule out surgery for many patients while providing additional variant and fusion information to help guide treatment for suspicious nodules. More than 400,000 patients have benefited from insights provided by Afirma GSC. As the most utilized molecular test for thyroid nodules in the Medicare population based on Medicare claims data*, Afirma is trusted by healthcare providers to support informed management decisions and to provide greater confidence in patient care. 🔗 Learn how Afirma GSC can support your thyroid nodule management - veracyte.com/tests/afirma-th… *Based on claims for CPT codes 81546, 0026U, 0245U as of 8/11/2026 – found at data.cms.gov/ Note: This article contains forward-looking statements, which involve risks and uncertainties. For more info visit - veracyte.com/legal/cautionar… #ThyroidCancerAwarenessMonth #ThyroidCancer #ThyroidNodules #MolecularTesting #PrecisionMedicine #AfirmaThyroid

Prostate Cancer Awareness Month (PCAM) is a time to focus on the people behind every diagnosis – and the questions, decisions, and care teams that shape each patient’s path forward. Behind every study, every test result, and every treatment decision is a person looking for answers. With that in mind, PCAM also serves as an opportunity to reflect on how ongoing research into tools such as genomic testing are helping inform more personalized conversations about prostate cancer care. Veracyte is incredibly proud that the Decipher® Prostate Genomic Classifier continues to help providers and patients get answers. Over the years, a wide-ranging collection of publications supports the use of the Decipher Prostate test in prostate cancer care decision-making, helping clinicians and their patients navigate treatment choices with clarity through genomic insights. Veracyte continues to build on that foundation. This work takes time, investment, and follow-through, and reflects Veracyte’s broader commitment to helping advance prostate cancer care. As we honor Prostate Cancer Awareness Month, our team wrote a piece to discuss the latest clinical research featuring the Decipher Prostate test and how it helps patients. | Key Topics Covered | 🔹 How the #DecipherProstate test works 🔹 Results from the ENZAMET Trial 🔹 The latest research on predicting cancer progression 🔹 A preview of new studies being presented at ASTRO 2026 🔗 For more, read the full piece here -  veracyte.com/company/blog/fr… #ProstateCancer #ProstateCancerAwareness #PrecisionMedicine Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - veracyte.com/legal/cautionar…